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Summary
Background Antibiotic-associated diarrhoea (AAD) occurs most frequently in older (≥65 years) inpatients exposed to 
broad-spectrum antibiotics. When caused by Clostridium diﬃ  cile, AAD can result in life-threatening illness. Although 
underlying disease mechanisms are not well understood, microbial preparations have been assessed in the prevention 
of AAD. However, studies have been mostly small single-centre trials with varying quality, providing insuﬃ  cient data 
to reliably assess eﬀ ectiveness. We aimed to do a pragmatic eﬃ  cacy trial in older inpatients who would be representative 
of those admitted to National Health Service (NHS) and similar secondary care institutions and to recruit a suﬃ  cient 
number of patients to generate a deﬁ nitive result.
Methods We did a multicentre, randomised, double-blind, placebo-controlled, pragmatic, eﬃ  cacy trial of inpatients 
aged 65 years and older and exposed to one or more oral or parenteral antibiotics. A computer-generated randomisation 
scheme was used to allocate participants (in a 1:1 ratio) to receive either a multistrain preparation of lactobacilli and 
biﬁ dobacteria, with a total of 6 × 10¹⁰ organisms, one per day for 21 days, or an identical placebo. Patients, study staﬀ , 
and specimen and data analysts were masked to assignment. The primary outcomes were occurrence of AAD 
within 8 weeks and C diﬃ  cile diarrhoea (CDD) within 12 weeks of recruitment. Analysis was by modiﬁ ed intention-to-
treat. This trial is registered, number ISRCTN70017204.
Findings Of 17 420 patients screened, 1493 were randomly assigned to the microbial preparation group and 1488 to 
the placebo group. 1470 and 1471, respectively, were included in the analyses of the primary endpoints. AAD 
(including CDD) occurred in 159 (10·8%) participants in the microbial preparation group and 153 (10·4%) 
participants in the placebo group (relative risk [RR] 1·04; 95% CI 0·84–1·28; p=0·71). CDD was an uncommon 
cause of AAD and occurred in 12 (0·8%) participants in the microbial preparation group and 17 (1·2%) participants 
in the placebo group (RR 0·71; 95% CI 0·34–1·47; p=0·35). 578 (19·7%) participants had one or more serious 
adverse event; the frequency of serious adverse events was much the same in the two study groups and none was 
attributed to participation in the trial.
Interpretation We identiﬁ ed no evidence that a multistrain preparation of lactobacilli and biﬁ dobacteria was 
eﬀ ective in prevention of AAD or CDD. An improved understanding of the pathophysiology of AAD is needed to 
guide future studies.
Funding Health Technology Assessment programme; National Institute for Health Research, UK. 
Introduction
Antibiotic-associated diarrhoea (AAD) occurs most 
frequently in older (≥65 years) inpatients exposed to 
broad-spectrum antibiotics, the risk increases pro gres-
sively with longer treatment courses, and it can occur up 
to 12 weeks after antibiotic exposure.1,2 The frequency of 
diarrhoea varies according to the antibiotic used, 
occurring in 2–20% of patients given cephalosporins, 
ﬂ uoroquinolones, macrolides, or tetracycline, 5–10% 
given ampicillin, and 10–25% given co-amoxiclav.1,2 
Additional recognised risk factors for AAD include 
prolonged hospital stay, treatment with proton pump 
inhibitors, use of a nasogastric tube, previous hospital 
admission, and previous gastrointestinal surgery.1,2
The main mechanism by which antibiotics cause 
diarrhoea is thought to be through impaired resistance to 
pathogens as a result of disruption of the gut microbial 
ﬂ ora and subsequent changes in the metabolism of 
carbohydrates, short-chain fatty acids, and bile acids.2,3
AAD is usually a mild and self-limiting illness 
but 15–39% of cases are caused by Clostridium diﬃ  cile, 
which can result in pseudomembranous colitis, toxic 
megacolon, and high case-fatality.4 Although some 
investigations have failed to identify high-risk anti-
biotics,5,6 cephalosporins, β-lactams, clindamycin, and 
more recently quinolones have been associated with 
C diﬃ  cile diarrhoea (CDD).7 Additionally, cumulative 
antibiotic exposure increases risk.7,8 Of great concern 
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since 2003 has been an increased frequency and severity 
of CDD associated with emergence of the hyper-
virulent 027 strain.9 This concern has led to concerted 
eﬀ orts to prevent infection through improved environ-
mental hygiene, handwashing, antibiotic stewardship, 
and isolation of patients with diarrhoea.10
In view of the proposed underlying disease mechan-
isms, several trials have assessed microbial preparations 
that might prevent or ameliorate AAD through anti-
pathogen eﬀ ects, such as secretion of bacteriocins, com-
petition for nutrients and binding sites, and enhance ment 
of the immunological barrier function and integrity of 
the gut mucosa.11 Meta-analyses have provided some 
evidence for the eﬃ  cacy of microbial preparations in 
prevention of AAD.12 However, substantial statistical 
heterogeneity in pooled results, attributable to variation 
in individual study results, undermined the ﬁ ndings.
Our hypothesis was that the administration of a 
microbial preparation would reduce the frequency of 
AAD and CDD in an at-risk population. We aimed to do a 
pragmatic eﬃ  cacy trial in older inpatients who would be 
representative of those admitted to National Health 
Service (NHS) and similar secondary care institutions 
and to recruit a suﬃ  cient number of patients to generate 
a deﬁ nitive result. On the basis of previous evidence,12 we 
selected a high-dose, multi-strain preparation of lacto-
bacilli and biﬁ dobacteria, the genera most frequently 
assessed in clinical trials. In this report, we have used the 
term microbial preparation and avoided probiotic, on the 
basis that the eﬀ ect of the intervention on prevention of 
AAD was unknown.13
Methods
Study design and participants
We did a multicentre, randomised, double-blind, 
placebo-controlled, two-group trial and have reported 
the trial protocol previously.14 Inpatients aged 65 years 
or older and exposed to one or more oral or intravenous 
antibiotics in the preceding 7 days, or about to start 
antibiotic treatment, were recruited by research nurses 
from medical and surgical wards of three hospitals in 
south Wales (Abertawe Bro Morgannwg University 
Health Board; ABMUHB) and two hospitals in northeast 
England (County Durham and Darlington Foundation 
Trust; appendix p 1). Exclusion criteria were existing 
diarrhoea, immunocompromised suﬃ  ciently to need 
isolation or barrier nursing, illness needing high 
dependency or intensive care, prosthetic heart valve, 
CDD in the previous 3 months, inﬂ ammatory bowel 
disease that had needed speciﬁ c treatment in the 
previous 12 months, suspected acute pancreatitis 
(abdominal pain with serum amylase or lipase more 
than three times the institutional upper limit of normal), 
known abnormality or disease of mesenteric vessels or 
coeliac axis, jejunal tube in situ or receiving jejunal 
feeds, previous adverse reaction to microbial prepar-
ations, and unwillingness to discontinue existing use of 
microbial preparations. In practice, patients who were 
nil by mouth or severely ill and not expected to survive 
for the period of follow-up were also not invited to join 
the study.
Patients provided signed informed consent or, when 
assessed to be unable to do so, signed assent was 
provided by relatives or carers. The Research Ethics 
Committee for Wales approved the study on Nov 27, 2008 
(No 08/MRE09/18).
Randomisation and masking
Eligible patients were allocated sequentially by research 
nurses in a 1:1 ratio to the two groups (placebo or 
microbial preparation) of the study, according to a 
computer-generated random sequence, stratiﬁ ed by 
centre and using blocks of variable size. The allocation 
sequence was generated by the independent statistician 
and not available to any member of the research team 
until databases had been completed and locked. 
Patients, study staﬀ , and specimen and data analysts 
were masked to assignment. In view of the established 
safety record of lactobacilli and biﬁ dobacteria15 there 
was no provision for emergency unmasking of partici-
pants and copies of the allocation sequence were not 
held at the recruiting centres.
Procedures
The microbial preparation was a lyophilised powder in a 
vegetarian capsule containing 6 × 10¹⁰ live bacteria: 
two strains of Lactobacillus acidophilus (CUL60, National 
Collection of Industrial, Food and Marine Bacteria 
[NCIMB] 30157; and CUL21, NCIMB 30156) and two 
strains of biﬁ dobacterium (Biﬁ dobacterium biﬁ dum 
CUL20, NCIMB 30153; and B lactis CUL34, NCIMB 30172). 
Identical placebo capsules contained inert maltodextrin 
powder. The dose was one capsule per day for 21 days 
with food and, when possible, between antibiotic doses. 
Unused capsules were collected opportunistically from 
some participants at the point of use for quantitative 
bacterial culture by an independent laboratory.
Research nurses collected baseline demographic data, 
characteristics of patients, and details of antibiotic 
therapy. Participants were followed up by research staﬀ  
daily during hospital admission and weekly by phone 
call after discharge. We had intended that follow-up 
would continue for 8 weeks after stopping antibiotics. 
In practice, pro longed follow-up for participants on 
long courses of antibiotics was not feasible and follow-
up was discon tinued at 8 weeks after recruitment. 
Changes to antibiotic treatment, the occurrence of 
diarrhoea, gastrointestinal symptoms, adverse events, 
and compliance with the trial interventions were 
recorded on standard forms.
We deﬁ ned diarrhoea as three or more loose stools 
(consistency 5–7 on the Bristol Stool Form Scale)16 in 
a 24 h period or as stools described as looser than normal 
in participants unable to use the scale. Stool samples 
See Online for appendix
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were collected only during episodes of diarrhoea and were 
analysed for Salmonella spp, Shigella spp, Campylobacter 
spp, Escherichia coli O157, and ova, cysts, and parasites in 
a wet ﬁ lm according to routine laboratory practice. 
Detection of viruses was done according to the clinical 
context and during suspected diarrhoea outbreaks. In 
ABMUHB, detection of C diﬃ  cile toxins was by an in-
house tissue culture assay with conﬁ rmation by enzyme 
immunoassay (Premier Toxins A&B; Meridian Bio-
science, Cincinnati, OH, USA). In the two hospitals in 
northeast England, the VIDAS Clostridium diﬃ  cile A & B 
assay (bioMérieux SA, Marcy l’Etoile, France) was used 
until June 2010, when detection of glutamate dehydro-
genase (C. DIFF QUIK CHEK; TECHLAB, Blacksburg, 
VA, USA) was used in conjunction with the toxin assay. 
Hospital laboratory records were reviewed for occurrence 
of diarrhoeal stools positive for C diﬃ  cile toxins 
until 12 weeks after recruitment.
Statistical analysis
The primary outcomes were the occurrence of AAD 
within 8 weeks and CDD within 12 weeks of recruitment. 
AAD was diarrhoea occurring in association with anti-
biotic therapy and without detection of diarrhoeal patho-
gens or an alternative explanation (eg, laxative treatment). 
Patients with AAD and a positive stool C diﬃ  cile toxin 
assay were diagnosed as CDD.
Secondary outcomes were severity and duration of 
AAD and CDD, abdominal symptoms, serious adverse 
events, duration of hospital stay, the acceptability of the 
microbial preparation, and quality of life. CDD was 
managed by the patient’s clinical team and severity of the 
episode classiﬁ ed according to UK national guidelines10 
from information collected from case records. Quality of 
life was assessed by the generic 12-item short form 
survey (SF12 v2),17 which was administered by research 
nurses at baseline, and 4 and 8 weeks. Additionally, we 
Figure 1: Trial proﬁ le
*Identity of trial intervention unknown because of an error in labelling at one hospital site. †Second enrolment in study excluded because of possible carry-over 
eﬀ ects from ﬁ rst enrolment in study. 
17 420 assessed for eligibility
2981 randomised 
1493 allocated to microbial preparation group 1488 allocated to placebo group
1487 received allocated intervention 1487 received allocated intervention
1470 analysed 1471 analysed
14 439 not recruited
 3202 excluded
 1026 existing diarrhoea
 680 active inﬂammatory bowel disease
 214 immunocompromised
 401 prosthetic heart valve
 307 known compromised gut blood supply
 201 continued live bacterial preparation
 191 Clostridium diﬃcile in past 3 months
 139 suspected acute pancreatitis
 39 needed high dependency or intensive care
 4 adverse reaction to previous probiotics
 9068 declined to participate
 2130 too unwell
 39 nil by mouth
6 did not receive allocated intervention
 6 trial intervention not known*
1 did not receive allocated intervention
 1 trial intervention not known*
17 excluded from analysis
 1 diarrhoea at recruitment
 1 Clostridium diﬃcile before recruitment
 1 continued live bacterial preparation
 1 details of antibiotic treatment not 
  available
 13 lost to follow-up
 6 participant declined, no reason given
 4 lost contact
 1 vomited after ﬁrst dose of trial 
  intervention and withdrew
 1 too unwell
 1 withdrawn by relative
16 excluded from analysis
 6 second recruitment to study†
 10 lost to follow-up
 6 participant declined, no reason given
 4 lost contact
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had intended to modify instruments validated to measure 
quality of life in treatment-induced diarrhoea in people 
with HIV18 and older patients with faecal incontinence.19 
In practice, we decided that completion of additional 
questionnaires was too onerous for older inpatients and 
these instruments were not pursued.
We estimated that AAD would occur in 20% and CDD 
in 4% of participants allocated to the placebo group. 
At the 5% signiﬁ cance level, 2478 participants (1239 in 
each group) were needed to detect a 50% reduction in 
CDD in the active group with 80% power and this sample 
size would provide a power of more than 99% to detect 
a 50% reduction in AAD and a power of 90% to detect 
a 25% reduction in AAD in the active group. We intended 
to recruit 2974 participants to allow for 10% dropout 
and 10% loss to follow-up.
Antibiotics were classiﬁ ed according to British National 
Formulary categories,20 indications for antibiotic treat-
ment according to the System Organ class, and serious 
adverse events according to Preferred Terms of the 
Medical Dictionary for Regulatory Activities.21
For the primary endpoint analysis, we calculated relative 
risks (RRs) and odds ratios (ORs) together with 
their 95% CIs using a generalised linear model that 
included treatment as one predictor. We analysed 
secondary endpoints in the same way. Additionally, we 
did a covariate-adjusted analysis for the primary outcome 
analysis by logistic regression, controlling for ten pre-
speciﬁ ed potential risk factors for AAD (centre, age, sex, 
antibiotic class, duration of antibiotic treatment, antacid 
therapy, nasogastric tube in-situ, previous gastro intestinal 
surgery, recent previous hospital admission, and duration 
of hospital stay). We summarised con tinuous variables 
using number of observations, median and IQR, or mean 
and SD, depending on variable distributions; we sum-
marised categorical variables by the number and percen-
tage of events. We also used χ² tests and Mann-Whitney 
methods for comparative purposes.
We calculated SF12 v2 quality-of-life subscales and 
component summary scores with imputation of missing 
values when possible.17 SF12 v2 subdomain, physical 
component summary score, and mental component 
summary score were allocated a value of 0 for the lowest 
(worst) score and 100 for the highest (best) score. We used 
mixed model analysis to assess change from baseline in 
SF12 v2 physical component summary and mental 
component summary scores at 4 weeks and 8 weeks in 
the two study groups. Baseline score was used as a 
covariate and treatment, visit, and interaction between 
the treatment and visit as ﬁ xed eﬀ ects; participant was a 
random eﬀ ect. Incomplete observations were assumed to 
be missing at random.
We did the analysis of study outcomes and safety in a 
modiﬁ ed intention-to-treat population, excluding the 
small number of participants who withdrew shortly after 
randomisation, did not receive the interventions, and did 
not have follow-up data. We also did a per-protocol 
analysis, excluding participants who did not receive any 
doses of the trial interventions or in whom compliance 
was unclear, and in those who took all 21, 14 or more, 
or seven or more doses of the trial interventions. We 
used SAS (version 9.2) for data analyses.
This trial is registered, number ISRCTN70017204.
Role of the funding source
The institutions funding the study had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. All authors had full access to all 
the data in the study. SJA had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Recruitment was done between Dec 1, 2008, and 
Feb 28, 2012. 2981 of 17 420 (17·1%) patients assessed 
for inclusion were recruited of whom 2941 (98·7%) 
were included in the analysis according to treatment 
Microbial preparation 
(n=1470)
Placebo
(n=1471)
Age (years) 77·2 (70·8–83·6) 77·0 (71·3–83·5)
Men 777/1470 (52·9%) 679/1471 (46·2%)
White ethnicity 1459/1461 (99·9%) 1461/1464 (99·8%)
Recruited during winter (October to March) 845/1470 (57·5%) 845/1471 (57·4%)
Hospital
Singleton 102/1470 (6·9%) 101/1471 (6·9%)
Morriston 742/1470 (50·5%) 737/1471 (50·1%)
Bridgend 94/1470 (6·4%) 97/1471 (6·6%)
Durham 269/1470 (18·3%) 278/1471 (18·9%)
Darlington 263/1470 (17·9%) 258/1471 (17·5%)
Admitted from
Home 1345/1469 (91·6%) 1334/1468 (90·9%)
Residential care 58/1469 (3·9%) 67/1468 (4·6%)
Other hospital 37/1469 (2·5%) 39/1468 (2·7%)
Other 29/1469 (2·0%) 28/1468 (1·9%)
Cigarette smoker 140/1470 (9·5%) 120/1471 (8·2%)
Drinks alcohol 459/1470 (31·2%) 482/1471 (32·8%)
Comorbid illnesses
Hypertension 779/1455 (53·5%) 812/1457 (55·7%)
COPD 350/1459 (24·0%) 354/1462 (24·2%)
Diabetes 357/1465 (24·4%) 314/1468 (21·4%)
Asthma 237/1462 (16·2%) 232/1465 (15·8%)
Renal disease* 127/1455 (8·7%) 139/1461 (9·5%)
Dementia or Alzheimer’s disease 61/1449 (4·2%) 80/1459 (5·5%)
Other 978/1452 (67·4%) 1010/1458 (69·3%)
Previous gastrointestinal surgery 203/1448 (14·0%) 212/1449 (14·6%)
Nasogastric tube in situ 5/1469 (0·3%) 2/1464 (0·1%)
Hospital admission in past 8 weeks 488/1470 (33·2%) 448/1471 (30·5%)
Live bacteria consumed in past 2 weeks† 72/1470 (4·9%) 45/1471 (3·1%)
Data are n/N (%) or median (IQR). COPD=chronic obstructive pulmonary disease. *Established by case note review by 
the research nurses and discussed with the patient’s physicians when necessary. †Self-reported consumption of live 
bacteria, probiotics, or live yoghurt. 
Table 1: Baseline characteristics of participants by treatment group
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allocated (ﬁ gure 1). The main reason for non-
recruitment was participants who declined to take part 
(9068, 52·1%), mainly because of unwillingness to take 
an additional medication.
Baseline characteristics were generally much the same 
in the 1470 participants assessed in the microbial 
preparation group and the 1471 in the placebo group 
(table 1). Indications for antibiotic treatment were much 
the same in the two study groups, with the most 
common indication being respiratory, thoracic, and 
mediastinal disorders (appendix p 2). Exposure to 
antibiotics was similar in the two groups (table 2). 
Median number of days between hospital admission and 
starting an antibiotic was 0 (IQR 0–1) in both groups 
(p=0·35). Non-antibiotic drug treatment was common 
and much the same in both groups; overall 48·1% 
(1395/2903) of participants were receiving anti hyper ten-
sive, 40·7% (1186/2916) aspirin, 39·4% (1149/2919) 
proton pump inhibitor, 29·7% (861/2902) angiotensin-
converting-enzyme inhibitor, 13·6% (396/2920) oral 
hypoglycaemic agent, 10·1% (293/2904) non-steroidal 
anti-inﬂ ammatory, 6·0% (174/2919) insulin, and 
5·9% (170/2903) H₂ blocker drugs.
AAD (including CDD) occurred in 10·6% (312) of 
participants overall with a similar frequency in both 
study groups (relative risk [RR] 1·04; 95% CI 0·84–1·28; 
p=0·71; odds ratio [OR] is about the same; table 3). Per-
protocol analysis showed much the same result (data not 
shown). In participants with AAD, stool samples were 
obtained for testing from 93 of 159 (58·5%) in the 
microbial preparation group and 88 of 153 (57·5%) in the 
placebo group. CDD was an uncommon cause of AAD 
and occurred in 0·99% (29) of participants with a similar 
frequency in each group (RR 0·71; 95% CI 0·34–1·47; 
p=0·35; OR is about the same; table 3). 
Covariate analysis identiﬁ ed that the occurrence of 
AAD was predicted by the duration of antibiotic treat-
ment, antacid therapy, and duration of hospital stay; 
CDD was predicted by duration of antibiotic treatment. 
The adjusted treatment eﬀ ect of the intervention on 
occurrence of AAD and CDD was much the same as the 
unadjusted eﬀ ect (appendix p 3).
In all participants during the 3 weeks when taking the 
trial interventions, abdominal symptoms and other 
morbidity were much the same in the study groups, 
except for small but statistically signiﬁ cant diﬀ erences 
in the frequency of ﬂ atus and having a nasogastric tube 
in situ (table 3). Morbidity was also similar in the two 
study groups throughout the whole period of follow-up 
(data not shown). Median duration of hospital admis-
sion was similar in the microbial preparation 
(n=1452; 4 days, IQR 1–11) and placebo groups (1447; 
4 days, 1–11; p=0·87; ﬁ gure 2).
Duration and severity of AAD and CDD and frequency 
of associated symptoms was much the same in the two 
intervention groups (appendix p 4) except that in CDD 
bloating was more common in the microbial preparation 
compared with the placebo group. Additional clinical 
signs, laboratory variables, and severity classiﬁ cation10 in 
patients with CDD were also similar in the two groups 
(appendix p 5). During the period of follow-up, no patient 
with CDD was identiﬁ ed as having pseudomembraneous 
colitis, needed colectomy, had a recurrence, or died from 
the illness.
Post-hoc analysis identiﬁ ed that most episodes of AAD 
(195/266, 73·3%) and CDD (22/29, 75·9%) occurred 
within 4 weeks of recruitment. Diarrhoea attributable to 
causes other than AAD occurred in seven (0·5%) 
Microbial preparation 
(n=1470)
Placebo
(n=1471)
Penicillins
Any* 1052 (71·6%) 1061 (72·1%)
Benzylpenicillin 115 (7·8%) 99 (6·7%)
Penicillinase resistant penicillin—ﬂ ucloxacillin 322 (21·9%) 310 (21·1%)
Broad-spectrum penicillins (amoxicillin, ampicillin, 
co-amoxiclav)
822 (55·9%) 829 (56·4%)
Anti-pseudomonas penicillins (piperacillin, piperacillin plus 
tazobactam)
127 (8·6%) 118 (8·0%)
Cephalosporins
Any* 359 (24·4%) 356 (24·2%)
First generation (cefalexin, cefradine) 77 (5·2%) 74 (5·0%)
Second generation (cefuroxime, cefaclor, ceﬁ xime) 290 (19·7%) 304 (20·7%)
Third generation (cefotaxime, ceftazidime, ceftriaxone) 11 (0·7%) 10 (0·7%)
Other antibiotics
Carbapenems and other β-lactams (ertapenem, imipenem, 
meropenem)
33 (2·2%) 29 (2·0%)
Tetracyclines (demeclocycline, doxycycline, lymecycline, 
oxytetracycline, tetracycline)
211 (14·4%) 222 (15·1%)
Aminoglycosides (gentamicin, tobramycin) 182 (12·4%) 196 (13·3%)
Macrolides (azithromycin, clarithromycin, erythromycin) 249 (16·9%) 251 (17·1%)
Clindamycin 18 (1·2%) 14 (1·0%)
Co-trimoxazole or trimethoprim 228 (15·5%) 242 (16·5%)
Metronidazole 171 (11·6%) 142 (9·7%)
Quinolones (ciproﬂ oxacin, levoﬂ oxacin, moxiﬂ oxacin, 
norﬂ oxacin)
185 (12·6%) 180 (12·2%)
Glycopeptides (teicoplanin, vancomycin) 103 (7·0%) 75 (5·1%)
Tuberculosis drugs (ethambutol, rifampicin, streptomycin) 26 (1·8%) 20 (1·4%)
Others (daptomycin, linezolid, nitrofurantoin, sodium fusidate) 38 (2·6%) 53 (3·6%)
Combination antibiotic therapy
1 class only 310 (21·1%) 310 (21·1%)
2 classes 407 (27·7%) 397 (27·0%)
≥3 classes 753 (51·2%) 764 (51·9%)
Duration of antibiotic therapy†
One dose 133 (9·5%) 123 (8·8%)
1–6 days treatment 389 (27·7%) 398 (28·5%)
7–13 days treatment 402 (28·6%) 426 (30·5%)
≥14 days treatment 482 (34·3%) 451 (32·3%)
Data are number (%) of participants who received therapy with the antibiotic during the period 7 days before recruitment 
to the end of follow-up at 8 weeks. * Some participants received more than one antibiotic in these classes. †Duration of 
therapy was known in 1406 participants in the microbial preparation group and 1398 in the placebo group.
Table 2: Antibiotic therapy by class and treatment group
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participants in the microbial preparation group and ten 
(0·7%) patients in the placebo group (RR 0·70; 95% CI 
0·27–1·84). In the microbial prepar ation group, six 
patients had norovirus diar rhoea and one was diagnosed 
with non-speciﬁ c colitis. In the placebo group, six patients 
had norovirus diarrhoea, one had diarrhoea after taking 
laxatives, two had drunk a large volume of fruit juice, and 
one had abnormal clotting and melaena.
Compliance with the trial interventions was known 
for 1462 participants in the microbial preparation 
and 1465 in the placebo group and was much the same in 
both study groups (ﬁ gure 3). 777 (53·1%) participants in 
the microbial prepar ation group and 766 (52·3%) in the 
placebo group were observed or reported as taking 
all 21 doses. The corresponding ﬁ gures for 14 or more 
doses were 1104 (75·5%) and 1106 (75·5%). Accounting 
for compliance in covariate analysis did not materially 
alter the risk of AAD (OR 1·02; 95% CI 0·80–1·30) or 
CDD (0·66; 0·30–1·47). 34 unused microbial preparation 
capsules collected at the point of use all contained at 
least 1·62×10¹⁰ viable bacteria and 33 placebo capsules 
tested were sterile.
578 (19·7%) participants had one or more serious 
adverse event; the frequency of serious adverse events 
was much the same in the two study groups (appendix 
pp 6–10). The most common events were respiratory, 
thoracic, and mediastinal disorders (83 of 1470 [5·6%] vs 
87 of 1471 [5·9%]); gastrointestinal disorders (44 [3·0%] 
vs 35 [2·4%]); and cardiac disorders (42 [2·9%] 
vs 28 [1·9%]) in the microbial preparation and placebo 
groups, respectively. No serious adverse event was 
attributed to participation in the trial.
SF-12 v2 mental component summary, physical 
component summary, and subscale scores were similar 
at baseline and, with the exception of vitality, tended to 
increase either by 4 or 8 weeks. Changes from baseline 
were much the same in each group (appendix p 11).
Discussion
Administration of a high dose preparation of lactobacilli 
and biﬁ dobacterium did not show the eﬀ ect of pre-
vention of AAD in our trial of nearly 3000 older 
inpatients. Analysis of secondary outcomes including 
diarrhoea severity, frequency of abdominal symptoms, 
length of hospital stay, and quality of life showed no 
evidence of a beneﬁ cial eﬀ ect attributable to the 
microbial preparation. Accounting for potential risk 
factors for AAD and compliance with the trial inter-
ventions did not signiﬁ cantly change the ﬁ ndings. Per-
protocol analysis produced consistent results with the 
intention-to-treat analysis.
As far as we are aware, our pragmatic study done in 
busy NHS hospitals is the largest trial so far for this 
problem (panel,12,22–32 ﬁ gure 429–32). By contrast with many 
previous trials,22 we conﬁ rmed the viability of the microbes 
at the point of use. Our study had several weaknesses. 
Although we attempted to minimise the exclusion criteria 
Microbial preparation Placebo OR (95% CI) p value
Antibiotic-associated diarrhoea
Antibiotic-associated 
diarrhoea*
159/1470 (10·8%) 153/1471 (10·4%) 1·04 (0·83–1·32) 0·72
Clostridium diﬃ  cile diarrhoea 12/1470 (0·8%) 17/1471 (1·2%) 0·70 (0·34–1·48) 0·35
Morbidity in the ﬁ rst 3 weeks after recruitment
Diarrhoea 189/1460 (12·9%) 172/1464 (11·7%) 1·12 (0·90–1·39) 0·33
Nocturnal diarrhoea 55/1459 (3·8%) 51/1464 (3·5%) 1·09 (0·74–1·60) 0·68
Faecal incontinence 46/1460 (3·2%) 53/1463 (3·6%) 0·87 (0·58–1·29) 0·48
Tenesmus 22/1458 (1·5%) 22/1464 (1·5%) 1·00 (0·55–1·82) 0·99
Abdominal pain 200/1458 (13·7%) 193/1464 (13·2%) 1·05 (0·85–1·29) 0·67
Nausea 228/1458 (15·6%) 207/1462 (14·2%) 1·12 (0·92–1·38) 0·26
Vomiting 124/1459 (8·5%) 110/1463 (7·5%) 1·14 (0·87–1·49) 0·33
Bloating 155/1457 (10·6%) 143/1464 (9·8%) 1·10 (0·87–1·40) 0·44
Flatus 183/1459 (12·5%) 149/1462 (10·2%) 1·26 (1·00–1·59) 0·045
Nasogastric tube in situ 8/1460 (0·5%) 1/1463 (<0·1%) 8·06 (1·01–64·48) 0·019
Other morbidity 442/1462 (30·2%) 463/1468 (31·5%) 0·94 (0·80–1·10) 0·44
Sought consultation for new 
health problem
238/1469 (16·2%) 257/1471 (17·5%) 0·91 (0·75–1·11) 0·36
Data are n/N (%). OR=odds ratio. *Includes Clostridium diﬃ  cile diarrhoea. 
Table 3: Antibiotic-associated diarrhoea and morbidity in the ﬁ rst 3 weeks after recruitment
Figure 2: Duration of hospital admission in all participants
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to patients clearly predisposed to diar rhoea and those who 
might be at speciﬁ c risk from bacterial supplements,15,33 
we recruited fewer than one in ﬁ ve eligible patients. The 
main reason for non-participation was the unwillingness 
of people already receiving medicines to take an additional 
preparation. This practical diﬃ  culty needs to be con-
sidered when developing novel interventions for older 
patients with many comorbidities. Ethnic diversity was 
low in our study but was representative of the local older 
populations.34 Despite the low conversion rate, we 
recruited from a range of medical and surgical wards 
in ﬁ ve hospitals and the baseline characteristics, 
comorbidity, and indications for antibiotic treatment 
suggest that our ﬁ ndings are relevant to older inpatients 
in NHS and similar secondary care settings.
Our trial suggests that properties common to many so-
called probiotic bacteria, such as the production of lactic 
acid, are not eﬀ ective against AAD in older inpatients. 
Systematic review
Several meta-analyses of trials of microbial preparations in the 
prevention of AAD have suggested a beneﬁ cial eﬀ ect12,23–25,28 
including the most comprehensive review so far (63 trials; 
11 811 participants), which reported that microbial 
preparations reduced the risk of AAD (random eﬀ ects analysis: 
RR 0·58; 95% CI 0·50–0·68).22 However, as in other reviews, the 
clinical trials included varied substantially in participant 
characteristics, the microbial preparations tested, antibiotic 
exposure, and trial settings, and the reliability of this pooled 
result was undermined by large statistical heterogeneity 
(I2=54%). Subgroup analyses accounting for these factors did 
not explain the heterogeneity. As in a Cochrane review28 of 
microbial preparations in the prevention of AAD in children, 
trial design and reporting were often poor.22
For the prevention of CDD, eﬃ  cacy of the microbial preparation 
in our study was consistent with the ﬁ ndings of a meta-
analyses (20 trials, 3818 people; random eﬀ ects model: RR 
0·34; 95% CI 0·24–0·49).27 Although there was consistency in 
results across studies, this meta-analysis included trials of many 
diﬀ erent microbes, including the yeast Saccharomyces boulardii, 
included both children and adults, and research methods and 
reporting were assessed to be poor in many studies. For both 
AAD and CDD, the variability in trials precludes the 
development of clinical guidelines.
In an attempt to reduce clinical heterogeneity, we restricted 
our search to randomised controlled trials that assessed 
lactobacilli and biﬁ dobacteria in older inpatients exposed to 
antibiotics. We searched Medline, the Cochrane Library of 
Systematic Reviews, CENTRAL and DARE from date of 
inception to April 2013, and Embase (from 1996 to April 2013) 
using the search terms “antibiotic-associated diarrhoea”, 
“probiotic*”, “Lactobacillus”, “Biﬁ dobacterium”, and “elderly” 
and also hand-searched the references from previous 
systematic reviews.
For AAD, we identiﬁ ed only four trials that either studied 
older patients29 or the participants recruited had an average 
age of older than 65 years30–32 (ﬁ gure 4). Although the pooled 
result showed a statistically signiﬁ cant risk reduction in AAD 
in patients receiving microbial preparations, the diﬀ erence 
was small and unlikely to be of clinical signiﬁ cance. 
Furthermore, despite limiting the scope of the studies, 
substantial statistical heterogeneity (I2=90%) undermines the 
reliability of this ﬁ nding.
For CDD, we identiﬁ ed only one previous trial that has reliably 
reported outcomes in this age group;32 CDD was reduced in 
participants receiving a combination of Lactobacillus casei 
DN-114 001, L bulgaricus, and Streptococcus thermophilus (none 
of 56; 0%) compared with those assigned placebo (nine of 53; 
17·0%). However, the frequency of CDD in the control group 
was high (17·0%) and patients were highly selected.26,32
Interpretation
Administration of a high dose preparation of lactobacilli and 
biﬁ dobacterium did not show the eﬀ ect of prevention of AAD in 
our trial of nearly 3000 older inpatients. Overall, we believe that 
there is insuﬃ  cient evidence to support the use of any microbial 
preparation for the prevention of AAD in older inpatients.
Panel: Research in context
Risk diﬀerence (95% CI)* WeightMicrobial preparation
Events Total
Allen et al, 2013
Beausoleil et al, 200730
Beniwal et al, 200331
Hickson et al, 200732
Stockenhuber et al, 200829
Total
Heterogeneity χ2=40·39, df=4, p<0·0001, I2=90%
Test for overall eﬀect Z=3·58, p=0·0003
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Figure 4: Meta-analysis of trials of lactobacilli or biﬁ dobacteria, or both, in the prevention of antibiotic-associated diarrhoea in older inpatients
*From Mantel-Haenszel ﬁ xed eﬀ ects analysis. 
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